2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 260-262
Clinical issues with T cell engagers (scheduling, out-patient delivery, CRS prophylaxis, tumor flare, maintenance). One abstarct on bone modifying therapy in myeloma that didn't fit elsewhere.
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

971 Timing of bone-modifying agents and skeletal-related events in patients with newly diagnosed multiple myeloma

Hamlet Gasoyan, DS, PhD, MPH, Kirti Arora, MD2, Alec Ingros, DO3, Girahnaz Baloch, MD4, Jeffrey D. Kovach, MSc5, Shahzad Raza, MD6, Jack Khouri, MD7, Nicholas J. Casacchia, PharmD, MS8, Evan Butsch9, Jason Valent, MD10, Michael Rothberg, MD, MPH11, Faiz Anwer, MD12
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic Akron General, Cleveland, Ohio, United States
3 Cleveland Clinic Akron General, Cleveland, Ohio, United States
4 Cleveland Clinic Akron General, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States

Introduction

Delays in and underuse of bone-modifying agents (BMAs) in newly diagnosed multiple myeloma (NDMM) have previously been documented in clinical practice, but their effect on skeletal-related events (SREs) remains unclear.

Methods

This retrospective cohort study used electronic health record data from a large, integrated health system in Ohio and Florida to identify adults with NDMM between January 2017 and December 2023 who received a triplet or quadruplet regimen within a year of diagnosis. The primary endpoint was incident SRE. It was defined as one or more of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including use of radioisotopes), surgery to bone (including vertebroplasty), or spinal cord compression, and the earliest occurrence of SRE after myeloma diagnosis was ascertained via manual chart review. The primary predictor was BMA receipt within ± 90 days of treatment initiation with a triplet or quadruplet regimen (yes/no). Fifteen a priori-identified potential confounders, including sex, age at diagnosis, race, ethnicity, year of diagnosis, urbanicity, area deprivation index, insurance type, treatment facility location, eGFR, ECOG performance status, Charlson Comorbidity Index (CCI), International Staging System stage, high-risk cytogenetics based on IMS/IMWG 2025 recommendations, and history of SRE at baseline, were used for overlap weighting to balance baseline characteristics between groups. Next, the type of systemic therapy used (triplet vs. quadruplet) and initial BMA agent were also controlled in the weighted, fully adjusted Cox proportional hazards regression model with robust standard errors (sandwich estimators). Patients were censored at the end of the study period (April 30, 2026), at the latest available follow-up in the EHR, if they died, or (administratively) 1 year after myeloma diagnosis date, as applicable.

Results

A total of 686 patients were identified; 524 received only a triplet, and 162 received quadruplet regimen. Mean (SD) age at diagnosis was 66.4 (10.0) years, 45.5% were female, 23.3% were Black, 73.0% were White, and 5.5% had Hispanic ethnicity; 71.1% had ECOG performance status of 0-1, 57.0% had eGFR ≥60 ml/min/1.73 m2, 29.9% had ISS stage 1 NDMM, 42.9% had CCI ≤2, and 52.6% did not have a history of SRE at the time of myeloma diagnosis.

During the study period, 72.6% received BMA, and 53.9% received it within ±90 days of systemic therapy initiation. Initial BMA therapy was denosumab for 92 and bisphosphonates for 406 patients. In a multivariable logistic regression model, baseline eGFR <60 (vs. ≥60) was negatively associated with BMA receipt within ±90 days (adjusted odds ratio [AOR], 0.64, 95% CI, 0.46-0.91), while micropolitan area of residence (vs. metropolitan, AOR, 2.17, 95% CI, 1.13-4.33) and history of skeletal-related events at baseline (vs. none, AOR, 2.61, 95% CI, 1.86-3.70) were positively associated. Of the patients with a documented reason for delayed BMA in their chart (171 out of 316), the most common primary barrier was dental clearance issues (n=128), followed by patient preference or other reasons (n=28), other health issues (n=13), and insurance-related issues (n=2). Overall, 33 patients (4.8%) developed osteonecrosis of the jaw during the study follow-up, with a median time from myeloma diagnosis to onset of osteonecrosis of the jaw of 948.0 days (IQR, 499.0-1157.0).

During the study follow-up through April 2026, a total of 204 (29.7%) patients experienced an incident SRE, with a median time from myeloma diagnosis to SRE of 167.5 days (IQR, 68.5-608.0). In the doubly robust analysis, the adjusted hazard of SRE at 1 year was 35% lower among patients who received BMA within ± 90 days of systemic treatment initiation, compared with those who received delayed or no BMA; the difference approached but did not reach statistical significance (adjusted hazard ratio, 0.65, 95% CI, 0.42-1.00, P=0.05).

Conclusions

Our findings suggest that delayed BMA initiation may increase the risk of incident SREs, although further studies are needed to confirm this signal. They also highlight the role of dental clearance-related issues in delaying BMA initiation in clinical practice.

Hamlet Gasoyan, DS, PhD, MPH: No relevant conflicts of interest to declare.